PT - JOURNAL ARTICLE AU - Flint, J P AU - Welstead, M AU - Cox, S R AU - Russ, T C AU - Marshall, A AU - Luciano, M TI - Multi-polygenic prediction of frailty highlights chronic pain and educational attainment as key risk and protective factors AID - 10.1101/2024.05.31.24308260 DP - 2024 Jan 01 TA - medRxiv PG - 2024.05.31.24308260 4099 - http://medrxiv.org/content/early/2024/05/31/2024.05.31.24308260.short 4100 - http://medrxiv.org/content/early/2024/05/31/2024.05.31.24308260.full AB - Frailty is a complex trait. Twin studies and recent Genome-Wide Association Studies have demonstrated a strong genetic basis of frailty but there remains a lack of genetic studies exploring genetic prediction of Frailty. Previous work has shown that a single polygenic predictor – represented by a Frailty polygenic score - predicts Frailty, measured via the frailty index, in independent samples within the United Kingdom. We extended this work, using a multi-polygenic score (MPS) approach to increase predictive power. Predictor variables - twenty-six polygenic scores (PGS) were modelled in regularised Elastic net regression models, with repeated cross-validation, to estimate joint prediction of the polygenic scores and order the predictions by their contributing strength to Frailty in two independent cohorts aged 65+ - the English Longitudinal Study of Ageing (ELSA) and Lothian Birth Cohort 1936 (LBC1936). Results showed that the MPS explained 3.6% and 4.7% of variance compared to the best single-score prediction of 2.6% and 2.2% of variance in ELSA and LBC1936 respectively. The strongest polygenic predictors of worsening frailty came from PGS for Chronic pain, Frailty and Waist circumference; whilst PGS for Parental Death, Educational attainment, and Rheumatoid Arthritis were found to be protective to frailty. Results from the predictors remaining in the final model were then validated using the longitudinal LBC1936, with equivalent PGS scores from the same GWAS summary statistics. Thus, this MPS approach provides new evidence for the genetic contributions to frailty in later life and sheds light on the complex structure of the Frailty Index measurement.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe LBC1936 is supported by the Biotechnology and Biological Sciences Research Council, and the Economic and Social Research Council [BB/W008793/1], Age UK (The Disconnected Mind Project, which also supported MW), the Milton Damerel Trust, and The University of Edinburgh. SRC is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (221890/Z/20/Z). ELSA is funded by the National Institute on Aging (R01AG017644), and by UK Government Departments coordinated by the National Institute for Health and Care Research (NIHR). No editorial service was provided. Funding Acknowledgements: This research was funded by the Legal & General Group (research grant to establish the independent Advanced Care Research Centre at the University of Edinburgh). The funder had no role in the conduct of the study, interpretation, or the decision to submit for publication. The views expressed are those of the authors and not necessarily those of legal and general.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics for ELSA have been approved via the South Central - Berkshire Research Ethics Committee (21/SC/0030, 22nd March 2021). PGS for ELSA were acquired through request to the ELSA genetics team (Ajnakina & Steptoe, 2019). Ethical permission for LBC1936 was approved from the Multi-Centre Research Ethics Committee for Scotland (Wave 1: MREC/01/0/56), the Lothian Research Ethics Committee (Wave 1: LREC/2003/2/29), and the Scotland A Research Ethics Committee (Waves 2, 3, 4 and 5: 07/MRE00/58). Written consent was obtained from participants at each of the waves. DNA was collected via blood samples from the majority of participants at wave 1 and genotyping was performed using stringent quality control measuresI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAvailability of data and material: Data was obtained from the Lothian Birth Cohort 1936, more information can be found at https://lothian-birth-cohorts.ed.ac.uk/. The English Study of Ageing data: ukdataservice.ac.uk/datacatalogue//series/series?id=200011. Any further data not found in such sources are available on request.